May 17, 2021 -- Soteria Biotherapeutics has closed $42 million in financing to launch as an immuno-oncology company focused on developing next-generation switchable, bispecific T-cell engagers to treat solid tumor cancers.
The company has developed T-Lite T-cell engagers that are selectively switched on through oral administration of a small-molecule activator to modulate potent T-cell activity by controlling the timing, duration, and level of bispecific complex formation. The switchable activity enables precise on/off control over the timing and magnitude of T-cell redirection and cytotoxic activity, according to the company.
The new funding will support the further advancement of the T-Lite technology platform and building of a pipeline of T-Lite candidates in validated cancer targets.
The series A financing was led by Roche Venture Fund and 5AM Ventures with participation from M Ventures, Novartis Venture Fund and Alexandria Venture Investments.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
